How does fampridine affect upper limb function in Multiple Sclerosis?

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1056294

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2018

Funding Scheme: Postgraduate Scholarships

Funding Amount: $113,237.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Neurology and Neuromuscular Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

central nervous system (CNS) diseases | electrophysiology | multiple sclerosis (MS) | neurophysiology | upper limb function

Related Links